• Since breast cancer is the most common cancer among women in the world or in Taiwan, the development of new drugs or new treatments strategy for breast cancer is warranted. Aimed to be a platform for Breast Cancer clinical trials in Taiwan, Taiwan Breast Cancer Consortium (TBCC), is formed.
• The consortium has been proven to prompt collaboration with international pharmaceutical and biotechnology companies as well as institutions in oncology clinical trials for breast cancer.
• We are also actively assisting Taiwan researchers to design investigators-initiated clinical trials, in line with international standards, and hope to let consortium become an excellent clinical trial alliance in Asia.
• To conduct the domestic breast cancer-related clinical trials 5. To explore new treatment strategies for treating breast cancers 6.To establish a common information-related platform for data collection of breast cancer and clinical daily application for breast cancer
• To explore new treatment strategies for treating breast cancers
• To establish a common information-related platform for data collection of breast cancer and clinical daily application for breast cancer

Academic Research:

• Taiwan Breast Cancer Consortium (TBCC) has been fully engaged in international multi-center trials, in which 15 articles are published in top medical journals (NEJM, LANCET ONCOL., JCO) as TBCC investigators co-authored in the past 3 years. Such as Chiun-Sheng Huang listed as 2nd author in Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine 380, 617-628 (2019) and Yen-Sen Lu as co-first author in Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine 381, 307-316 (2019)


• TBCC investigators are actively engaged to present research works in international meetings and seminars, such as American Society of Clinical Oncology (ASCO); San Antonio Breast Cancer Symposium (SABCS); and ESMO Asia Congress.


• For international multicenter trials, TBCC investigators sit in Steering Committee in 10 trials, and took a role as Global Chair / Co-chair in 4.

International Collaboration:

Up to more than 60 international multi-centers, Phase 2 or 3 trials with more than 1600 enrolment have been jointly conducted by member hospitals, where 12 of them are in recruitment while 22 are in follow-up / analysis.

Assistance to Domestic Pharmaceutical Companies

Conducting Phase III clinical trial for domestic EirGenix and OBI Pharma to assist with new drug approval.

Assistance of principle investigators-initiated clinical trials

We are convinced that the success of TBCC will bring impact to promoting Taiwan’s international status in the field of breast cancer clinical trial.